Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives

Ruben Malmberg; Bram C. Agema; Maaike M. Hofman; Stefani Oosterveld; Sander Bins; Daphne W. Dumoulin; Arjen Joosse; Joachim G. J. V. Aerts; Reno Debets; Birgit C. P. Koch; Astrid A. M. van der Veldt; Roelof W. F. van Leeuwen; Ron H. J. Mathijssen

doi:10.1002/cac2.12661

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) : 465 -470. DOI: 10.1002/cac2.12661

LETTER TO THE JOURNAL

Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives

Author information +

History +

PDF

Cite this article

Download citation ▾

Ruben Malmberg, Bram C. Agema, Maaike M. Hofman, Stefani Oosterveld, Sander Bins, Daphne W. Dumoulin, Arjen Joosse, Joachim G. J. V. Aerts, Reno Debets, Birgit C. P. Koch, Astrid A. M. van der Veldt, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen. Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives. Cancer Communications, 2025, 45(4): 465-470 DOI:10.1002/cac2.12661

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Malmberg R, Zietse M, Dumoulin DW, Hendrikx J, Aerts J, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022; 23(12): e552–e61.

[2]

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, et al. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective. Lung Cancer. 2024; 196: 107950.

[3]	Dubé-Pelletier M, Labbé C, Côté J, Pelletier-St-Pierre AA. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer. Oncologist. 2023; 28(11): 969–77.

[4]

Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer Guidance for Industry: U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER); 2022 [cited 2024 January 30th]. Available from: https://www.fda.gov/media/151745/download

[5]	Review Memo: Supplemental Biologics License Application for Pembrolizumab 400 mg every six weeks: US Food and Drug Administration; 2020 [updated April 13th; cited 2021 December 13th]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf

[6]	Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, et al. Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology. Clin Pharmacol Ther. 2021; 110(1): 200–9.

[7]	Assessment report Keytruda Procedure No. EMEA/H/C/003820/II/0065: European Medicines Agency; 2019 [cited 2022 February 24th]. Available from: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf

[8]	Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, et al. Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res. 2018; 24(23): 5841–9.

[9]	Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020; 131: 68–75.

[10]	Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022; 113(10): 3303–12.

[11]	Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, et al. The tyranny of non-inferiority trials. Lancet Oncol. 2024; 25(10): e520–e5.

[12]	Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017; 44(5): 403–14.